Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New allergy tablet could help millions breathe easier

NCT ID NCT07060885

Symptom relief Sponsor: ALK-Abelló A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This phase 3 trial tests a daily tablet that dissolves under the tongue to treat house dust mite allergies. It includes 327 Chinese participants aged 12-65 with allergic rhinitis, with or without asthma. The goal is to see if the tablet reduces allergy symptoms and the need for other medications over a 4-week period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
house dust mite allergy tablet (SLIT-tablet)
What this could lead to
If it works, this could offer a convenient daily tablet to ease allergy symptoms and reduce the need for other allergy medications.
What could go wrong
This is a phase 3 trial, but results may not apply to all populations. Some participants may still have symptoms or experience side effects like mouth itching or swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

327 people

The number who actually took part.

Started

Sep 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female Chinese subjects aged 12-65 years * A clinical history of HDM AR/C (Allergic rhinitis/rhinoconjunctivitis) (with or without asthma) and with allergic rhinitis symptoms despite having received allergy pharmacotherapy during the previous year prior to screening * Have a certain level of AR (Allergic rhinitis) symptoms on at least 8 of the last 14 days of the baseline period * Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the last 14 days of the baseline period * Positive skin prick test (SPT) and IgE (Immunoglobulin E) to D. pteronyssinus or D. farinae at screening * Lung function ≥ 70% of predicted value Exclusion Criteria: * Sensitised and regularly exposed to perennial allergens * Any nasal or pharyngeal condition that could interfere with the safety or efficacy evaluation * Asthma requiring treatment with high dose of inhaled corticosteroid * A relevant history of systemic allergic reaction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic rhinitis Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic rhinitis Allergic rhinoconjunctivitis

Contacts and locations

Locations

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100730, China

  • Fujian Provincial Hospital

    Fuzhou, Fujian, 350001, China

  • Hainan General Hospital - Respiratory

    Haikou, Hainan, 570311, China

  • Huazhong University of science and Technology Union Shenzhen Hospital(Nanshan Hospital) - Endocrinology

    Shenzhen, Guangdong, 518052, China

  • Jiangsu Province Hospital/ The First Affiliated Hospital with Nanjing Medical University - Otorhinolaryngology

    Nanjing, Jiangsu, 210029, China

  • Jingzhou Central Hospital - Otorhinolaryngology

    Jingzhou, Hubei, 434020, China

  • Nanchang University - The First Affiliated Hospital

    Nanchang, Jiangxi, 330046, China

  • Peking Union Medical College Hospital

    Beijing, Sichuan, 100730, China

  • Shanghai Jiaotong University School of Medicine, Ruijin Hospital

    Shanghai, Shanghai Municipality, 200025, China

  • Shenzhen Children's Hospital - Respiratory

    Shenzhen, Guangdong, 518026, China

  • Sichuan University - West China Second University Hospital (WCSUH) (West China Women's and Children's Hospital)

    Chengdu, Sichuan, 610017, China

  • The 2nd School of Medicine, WMU/The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU - Pediatrics

    Wenzhou, Zhejiang, 325027, China

  • The Fifth Affiliated Hospital of Sun Yat-Sen University - University Hospital

    Zhuhai, Guangdong, 510275, China

  • The First Affiliated Hospital of Chongqing Medical University - Respiratory

    Chongqing, Sichuan, 400016, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021, China

  • The First Affiliated Hospital of Soochow University - Respiratory

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital of University of South China - Endocrinology

    Hengyang, Henan, 421001, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region - Nephrology - Oncology

    Nanning, Guangxi, 530021, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330047, China

  • The Second Affiliated Hospital of Xi an Jiaotong University (Xibei Hospital) - Nephrology

    Xi'an, Shaanxi, 710004, China

  • The Third Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510630, China

  • The Third Affilliated Hospital of Southern Medical University

    Guangzhou, Guangdong, 510630, China

  • The Third Hospital of Changsha - Pulmonology

    Changshacun, Henan, 410015, China

  • The first affiliated hospital of guangzhou medical university-respiratory department

    Guangzhou, Guangdong, 510120, China

  • The first hospital affiliated Fujian medical University

    Fuzhou, Fujian, 350005, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, 430030, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology - Oncology

    Wuhan, Hubei, 430022, China

  • West China Hospital of Sichuan University - Otorhinolaryngology

    Chengdu, Sichuan, 610041, China

  • Zhejiang provincial people's hospital

    Hangzhou, Zhejiang, 310014, China

  • Zhongshan Hospital

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.